DalCor Pharmaceuticals, a company developing precision treatments by genetically targeting patients that will derive clinical benefits, has named Dr Fouzia Laghrissi-Thode as its director, it was reported yesterday.
The new director is vice-president at AstraZeneca. She has been leading the US Renal-Cardiology Therapeutic Area based in San Francisco and earlier led the Global Cardiovascular Metabolism Therapeutic Area.
In addition to her cardiovascular experience, Dr Laghrissi-Thode has demonstrated success at Roche, Novartis and Sandoz in clinical development, global strategic marketing, business development and licensing in various therapeutic areas including diabetes, renal and the central nervous system. She drove the development of Dalcetrapib and the Dal-HEART program at Roche. She also served as a board member of the Healthcare Businesswomen's Association Europe and was recognised by HBA in 2012 for her work in developing and promoting women leadership in healthcare.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes